Key facts
- Heart Biotech’s last known valuation is $27.4M (Nov 2024).
- It has raised $6.4M; the latest was Later Stage VC ($2.6M) in Nov 2025.
- Notable investors include Innovate UK, MedTech Innovator, Norn Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Heart Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Heart Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Heart Biotech
Developer of regenerative implants designed to restore natural tissue function in cardiovascular patients. The company specializes in bioengineered scaffolds featuring cell-free regenerative materials, dynamic tissue-shaping design, and full resorption capability, enabling pediatric and adult patients to regenerate living heart valves that grow, adapt, and eliminate the need for repeat surgeries.
- Sector
- Healthcare
- HQ
- Winchester, United Kingdom
- Founded
- 2014
- Employees
- 5
- Website
- heartbiotech.co.uk/
- Ownership
- Privately Held (backing)
Heart Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heart Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heart Biotech in its N-PORT filings yet. We sweep new filings monthly.